Field 3 – Biomarker research, development, and validation

This field will provide access to cutting-edge and high-quality services (e.g., liquid biopsies, imaging biomarkers including radiomics, microbiomics, omics signatures, etc.) that will support the optimization of existing screening programs, the advancement of novel approaches for screening and early detection, identification of new biomarker sets, as well as will contribute to the development of novel therapeutics based on molecular predictors. Advanced approaches will provide the means to identify (multivariate) biomarker sets, ascertain whether biomarkers are reactive or causative, validate them and, ultimately, use them to, among the others, assist the design stratification or intervention strategies, and clinical decision support systems. Access to biomarker-related services will be provided by multiple institutions with solid expertise and capacity to cutting-edge technological services. Moreover, for services provided in this field to be successful, a close collaboration and cross-fertilisation with field 2 is needed. The two fields will work together in order to deliver complementary services for personalised approaches. 

Unique IDCountryService Name Description of ServiceResearch InfrastructureService ProviderUnit of accessWebsite
3.32_CBMEDATCirculating tumor cell isolation from  peripheral blood Circulating tumor cells are isolated from peripheral blood of tumor patients and characterized.BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) Center for Biomarker Research in Medicine GmbHCTC isolation and analysis from 1 patienthttps://www.cbmed.at/
3.37_CBMEDATDesign of mRNA padlock probes Design and optimization of mRNA padlock probes targeting genes of interest. mRNA padlock probes are long oligonucleotides, whose ends are complementary to adjacent target sequences. Upon hybridization to the target, the two ends are brought into contact, allowing PLP circularization by ligation.BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) Center for Biomarker Research in Medicine GmbHDesign of padlock probes for 1 gene of interesthttps://www.cbmed.at/
3.38_CBMEDATApplication of mRNA padlock probes on sample materialApplication of mRNA padlock probes on isolated CTCs from tumor patients. mRNA padlock probes are long oligonucleotides, whose ends are complementary to adjacent target sequences. Upon hybridization to the target, the two ends are brought into contact, allowing PLP circularization by ligation.BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) Center for Biomarker Research in Medicine GmbHPerforming of 1 padlock assay experimenthttps://www.cbmed.at/
3.44_IDISESBiomarker's validation (PET imaging)The service provides the validation of clinical imaging biomarkers, especially assessing variability related with Physics and scanner-related effects. In particular, Monte Carlo simulation for producing realistic simulations of clinical images on different conditions (i.e. different scanners, reconstruction methods, noise conditions, etc...), is used to evaluate the estability of biomarkers over different conditions. The service provider developed the platform SimSET and has access to the CESGA supercomputing capabilities for the needed computational resources (https://www.cesga.es/en/home-2/) EATRIS ERIC (EATRIS)Health Research Institute of Santiago de Compostela (IDIS)Biomarker's validation (PET imaging)https://www.idisantiago.es/
3.15_ISSITTargeted phospho-proteomics for studying the most relevant pathways in cancerTargeted phospho-proteomics using 60 antibodies selectable among >400 covering the most relevant pathways in cancer, i.e. RTKs, PI3K/mTOR, MAPKs, autophagy, apoptosis, metabolism, cell adhesion and migration, cell cycle regulation and checkpoints, DNA damage, hypoxia as well as inflammation and immunityEATRIS ERIC (EATRIS)Istituto Superiore di Sanità (ISS)A single RPPA experiment incl. up to 1000 sampleshttps://www.iss.it/
3.28_ISSITImmuno proteomic profilingAnalysis of cytokine, chemokine and immune factors in human biological samples (serum, plasma, CSF, vitreous, saliva, tears, tumors samples) using Bio-Plex Assays -(Luminex thechnologies)EATRIS ERIC (EATRIS)Istituto Superiore di Sanità (ISS)Run (10 samples)https://www.iss.it/
3.40_ISSITSorting for Extracellular vescicles (Evs)Analysis of fluorescent labelled EVs (cytoflex) - Sorting of fluorescent labelled EVs (MoFlow Astrios)EATRIS ERIC (EATRIS)Istituto Superiore di Sanità (ISS)1 Hourhttps://www.iss.it/
3.16_UiBNOMass Cytometry (Helios/Cytof XT)Immune profiling with a fixed 30 antibody panel including barcoding (20-plex)EATRIS ERIC (EATRIS)University of Bergen (UiB)1x 20-Plex samplehttps://www.uib.no/en
3.20_IIS LA FEES End-to-end analysis pipelines for radiogenomics studies (integration of biological and imaging biomarkers) Radiogenomics is a discipline that identifies correlations between radiomic and dynamic parameters, as phenotypic data obtained from images can be correlated with tissue genome profiles and related molecular transcriptional activities. This service provides an end-to-end pipeline to perform such correlations by using statistical approaches and visual analysis of clusters (e.g., heat maps and dendrograms) with the objective to help the treatment selection by providing individual-level rather than population-level information.EATRIS ERIC (EATRIS)Instituto de Investigación Sanitaria La Fe (IIS La Fe)Studyhttps://www.iislafe.es/en
3.21_SDN SpAITMultiparametric immunophenotype of blood/immune cells as well as solid tumor cells by flow cytometryThe service is intended for defining bone marrow and peripheral blood immune cells as well as solid tumor-infiltrating immune cells using state-of-the-art FCM protocolsEATRIS ERIC (EATRIS)Network of Neuroscience and Neurorehabilitation IRCCS Samplehttps://www.reteneuroscienze.it/en/Istituto/irccs-sdn-istituto-di-ricerca/
3.31_SDN SpAITUltrasensite determination of biomarkers (i.e. circulating cytokines, Neurofilaments light chains, etc.) using the SIMOA technology for biomarker discovery and validationThe service is based on the SIMOA technology, a cutting-edge method for detecting circulating biomarkers. This technology also allows a fine detection of inflammatory cytokines in serum or plasma samples.EATRIS ERIC (EATRIS)Network of Neuroscience and Neurorehabilitation IRCCS Multisample Platehttps://www.reteneuroscienze.it/en/Istituto/irccs-sdn-istituto-di-ricerca/
3.27_Immunobiol. Group_CHUCPTCharacterization of immunophenotypes and immune-monitoringIdentification and quatification of the tumour immune infiltrate by flow cytometry, including Th1, Th2, Th17 and Treg cells, and their plasticity, cytotoxic T cells, γδ T cells, and double negative αβ T cells, M1 and M2 macrophages. Study of the expression of immunosuppressive molecules and/or their receptors by tumour cells, immune cells infiltrating the tumour, and their peripheral blood counterparts, including PD-1/PD-L1, IDO, CD39/CD73/A2A adenosine receptor (ADORA2A), CD200/CD200R, and TIM-3.EATRIS ERIC (EATRIS)Centro Hospitalar e Universitário de Coimbra (CHUC)Sample for Charact. of imm.phenot. & imm.monitor.https://www.chuc.min-saude.pt/
3.30_IDIVALES Immunemonitoring-Immune-checkpoints panel:
LAG3/ICOSL/CTLA-4/BTLA4/CD3/-/PD-1/CD4/PD-L1/-
Immuno-monitoring study using a specific panel: LAG3/ICOSL/CTLA-4/BTLA4/CD3/-/PD-1/CD4/PD-L1/-EATRIS ERIC (EATRIS)Valdecilla Biomedical Research Institute - IDIVALPanel/Samplehttps://www.idival.org/en/home/
3.34_Lab of molecular biol. IRCCSITBiomarkers discovery from liquid biopsies: exosomal microRNA (miRNA), ctDNA, and validation of miRNAs profilesAnalysis of miRNA, ctDNA and validation or miRNA profiles by RTqPCREATRIS ERIC (EATRIS)IRCCS Istituto Giannina Gaslini (IGG)Samplehttps://www.gaslini.org/
3.39_Nanobiomics_IRSTITCirculating Tumor Cells CharacterizationDetection and characterization of circulating tumor cells (phenotypic and copy number alteration and single nucleotide variations) , extracellular vesiscles (phenotypic and cargo), free circulating nucleic acids (gene mutation panel assay, shallow WGS, RNASeq, miRNASeq).EATRIS ERIC (EATRIS)Istituto Tumori della Romagna IRST IRCCSSample for Det. & character. of circul. tumor cellhttps://www.irst.emr.it/it/
3.51_KTH Royal Institute of TechSEDevelopment and analytical validation of multiplexed immunoassays for verification and validation of protein biomarkers in body fluids. The technologies implemented for de novo assay development are Luminex and Simoa (Quanterix). The affinity reagents used for assay development are tested for specificity. Further screening of antibodies to identify working antibody pairs for the biomarker of interest are part of the assay development.The cost include analytical development and verification on ~400 samples. Cost however will depend on the number of biomarkers and assay type.EATRIS ERIC (EATRIS)KTH Royal Institute of TechnologyDevelopment, validation and application of a new assays for circulating biomarkershttps://www.kth.se/en
3.46_Translational Biomark.Gr_IBBLLUBiomarkers Pre-analytical validation Assessment and reporting of the robustness of your biomarker to common pre-analytical variables such as sample processing delays, storage and processing temperatures and freeze-thaw cyclesEATRIS ERIC (EATRIS)Integrated Biobank of Luxembourg (IBBL)Pre-analytical validation of one Biomarkerhttps://www.lih.lu/en/translational-medicine/translational-medicine-operations-hub/integrated-biobank-of-luxembourg-ibbl/
3.47_Group_IBBLLUBiomarkers Analytical validationAssessment and reporting of the analytical characteristics of your biomarker assay including, amongst others, precision, matrix effect, analytical range, specificity, sensitivity and stabilityEATRIS ERIC (EATRIS)Integrated Biobank of Luxembourg (IBBL)Biomarkerhttps://www.lih.lu/en/translational-medicine/translational-medicine-operations-hub/integrated-biobank-of-luxembourg-ibbl/
3.48_Group_IBBLLUBiomarkers Clinical verification Study on a limited sample size to verify the performance of your biomarker in clinical sample sets presenting the same clinical characteristics of the initial POC populationEATRIS ERIC (EATRIS)Integrated Biobank of Luxembourg (IBBL)Biomarkerhttps://www.lih.lu/en/translational-medicine/translational-medicine-operations-hub/integrated-biobank-of-luxembourg-ibbl/
3.41_Clog-liver_IGTPES Liver cancer platform for biomarker validationAssessment and reporting of a specific biomarker in clinical samples of liver cancer. The technique used will depend on the nature of the biomarker (eg, in case of secreted proteins we will prioritize ELISA in plasma; in case of gene expression biomarkers, we will study RNAseq data or qPCR data). The study includes the statistical analysis with clinical and pathological features to determine the diagnostic and prognostic potential of the selected biomarker.EATRIS ERIC (EATRIS)Institute for Health Science Research Germans Trias i Pujol (IGTP)Biomarker validation for 22 sampleshttps://www.germanstrias.org/es/
3.42_Mol.& Struct. Patho IGTPES Immunohistochemical validation of selected biomarkersAutomatized immunohistochemical staining for biomarkers assessment in human tissues. Samples usually correspond to paraffin blocks, including tissue microarrays, from formalin fixed tissues. Immunohistochemistry on frozen tissue can be also considered upon agreement. This service does not include interpretation of the results. EATRIS ERIC (EATRIS)Institute for Health Science Research Germans Trias i Pujol (IGTP)1 glass slide stained with 1 antibodyhttps://www.germanstrias.org/es/
3.4c_MRIFIPreclinical Magnetic Resonance ImagingMagnetic resonance imaging (MRI) of animal models, comprising a large number of techniques for various applications ranging from simple morphological measurements to the evaluation of molecular processes at the cellular level.
Used to monitor disease development and to test the efficacy of therapeutic treatments, to develop novel diagnostic tools etc. Several quantitative MR imaging biomarkers can be used to monitor disease progression over time.
The service includes animal model preparation, provision of contrast agents (with possibility of custom synthesis of specific targeting and/or theranostic probes if needed), image data processing and analysis.
EURO-BIOIMAGING ERIC (EURO-BIOIMAGING)Finnish BioMedical Imaging Nodecomplete accesshttps://www.eurobioimaging.eu/nodes/finnish-biomedical-imaging-node
3.6_image analysis_Erasmus MCNLMedical Image data analysisAdvanced image analysis tools and pipelines for clinical studies; machine learning and artificial intelligence tools for high volume medical image processing and analysis aimed at prospective epidemiological studies on the population and clinical level and imaging biomarkers discovery. Specific imaging biomarkers can be used to investigate causes of pathological alterations and to identify people at risk of developing disease or disease progression.EURO-BIOIMAGING ERIC (EURO-BIOIMAGING)Population Imaging Node Rotterdamcomplete accesshttps://www.eurobioimaging.eu/nodes/population-imaging-flagship-node-rotterdam
3.3b_Call Observatory and NCINLHigh Throughput Microscopy/High Content Screening High-throughput microscopy has created new opportunities for studying biological phenomena in an unbiased manner. Using automated cell manipulations and microscopy platforms, it is possible to easily screen entire genomes for genes that affect any cellular process that can be visualized. HTM techniques rely on fully automated widefield or confocal microscopy systems which facilitate the capture of thousands of images, often in multi-well plates. Labs supporting HCS also have the expertise to automatically deliver drugs to multiwell plates, and to handle, process and analyse thousands of images using high-content screening analysis methodologies. EURO-BIOIMAGING ERIC (EURO-BIOIMAGING)High Throughput Microscopy Dutch Flagship NodeComplete accesshttps://www.eurobioimaging.eu/nodes/high-throughput-microscopy-dutch-flagship-node
3.4a_PETPTPreclinical PET Imaging and AutoradiographyPositron Emission Tomography (PET) Imaging of animal models, for monitoring function and metabolism. The service includes radiotracer provision, animal model preparation, image data processing and analysis. Suitable radioisotopes and tracers can be selected based on the processes/targets that need to be visualized. EURO-BIOIMAGING ERIC (EURO-BIOIMAGING)Brain Imaging Networkhourhttps://www.eurobioimaging.eu/nodes/brain-imaging-network-bin
3.4b_PET and SPECTNLPreclinical PET and SPECT imagingPositron Emission Tomography (PET) and Single Photon Emission Tomography (SPECT) Imaging of animal models, for monitoring function and metabolism. The service includes radiotracer provision, animal model preparation, image data processing and analysis. Suitable radioisotopes and tracers can be selected based on the processes/targets that need to be visualized. EURO-BIOIMAGING ERIC (EURO-BIOIMAGING)Preclinical Imaging Centrehourhttps://www.eurobioimaging.eu/nodes/preclinical-imaging-centre-(prime)---molecular-imaging-dutch-node
3.3a_High-content imag.FIHigh Throughput Microscopy/High Content Screening High-throughput microscopy has created new opportunities for studying biological phenomena in an unbiased manner. Using automated cell manipulations and microscopy platforms, it is possible to easily screen entire genomes for genes that affect any cellular process that can be visualized. HTM techniques rely on fully automated widefield or confocal microscopy systems which facilitate the capture of thousands of images, often in multi-well plates. Labs supporting HCS also have the expertise to automatically deliver drugs to multiwell plates, and to handle, process and analyse thousands of images using high-content screening analysis methodologies. EURO-BIOIMAGING ERIC (EURO-BIOIMAGING)Finnish Advanced Microscopy Nodehourhttps://www.eurobioimaging.eu/nodes/finnish-alm-node---advanced-light-microscopy-finnish-node
3.15_NORMOLIM Optical imag.NOIn vivo optical imagingIn vivo preclinical optical Imaging, for for visualizing and characterizing tumors and for imaging guided surgery. Fluorescence, bioluminescence and other optical imaging techniques are available. A variety of bioluminescent and/or fluorescent probes can be used, each targeted to a specific tissue or molecular or cellular event.
Animal model preparation, probes and image data processing and analysis are included in the service.
EURO-BIOIMAGING ERIC (EURO-BIOIMAGING)NORMOLIM - Norwegian Molecular Imaging Infrastructurehourhttps://www.eurobioimaging.eu/nodes/normolim,-norwegian-molecular-imaging-infrastructure
3.5_Optical Imag.ITIn vivo optical imagingIn vivo preclinical optical Imaging, for for visualizing and characterizing tumors and for imaging guided surgery. Fluorescence, bioluminescence and other optical imaging techniques are available. A variety of bioluminescent and/or fluorescent probes can be used, each targeted to a specific tissue or molecular or cellular event.
Animal model preparation, probes and image data processing and analysis are included in the service.
EURO-BIOIMAGING ERIC (EURO-BIOIMAGING)MultiModal Molecular Imaging Italian Nodecomplete accesshttps://www.eurobioimaging.eu/nodes/molecular-imaging-italian-node
3.49_WURNLMicrobiome geno- and phenotypingFunctional metagenomics and phenotypingIBISBA (WAGENINGEN UNIVERSITY)Wageningen University & Research Microbiome geno-and phenotypinghttps://www.wur.nl/en/about-wur.htm
3.50a_XPEOITAdvanced profiling (NGS, IHC, IF) of a patient-derived xenograft (PDX) model.Generation of molecular profiles (e.g., DNA-seq, RNA-seq, Immunohistochemistry, other) on a PDX model, either provided by the user or selected from the EurOPDX collection. The standard service (1x Unit of Access) involves generating one type of profile on one sample. To perform more complex studies, more units of access must be selected. For instance, for a combined DNA-seq/RNA-seq profiling on one PDX, 2x Units of access are required. The service can be combined with drug efficacy testing, e.g., to profile PDXs after in vivo treatment.
This service is open to both Academic and Industry researchers.
EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO)University of Torino1 PDX modelhttps://www.oncology.unito.it/
3.50b_CELLAX_Exp. TherapeuticsES Advanced profiling (NGS, IHC, IF) of a patient-derived xenograft (PDX) model.Generation of molecular profiles (e.g., DNA-seq, RNA-seq, Immunohistochemistry, other) on a PDX model, either provided by the user or selected from the EurOPDX collection. The standard service (1x Unit of Access) involves generating one type of profile on one sample. To perform more complex studies, more units of access must be selected. For instance, for a combined DNA-seq/RNA-seq profiling on one PDX, 2x Units of access are required. The service can be combined with drug efficacy testing, e.g., to profile PDXs after in vivo treatment.
This service is open to both Academic and Industry researchers.
EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO)Vall d'Hebron Institute of Oncology1 PDX modelhttps://vhio.net/
3.45a_XPEOITIn vivo preclinical validation of response predictors (biomarkers).Performance of an in vivo drug efficacy study on a selected patient-derived xenografts (PDX) model. The standard service (1x Unit of Access) involves testing a user-provided drug or compound and a list of biomarkers in a 2-arms study, one control arm and one treatment arm, with 6 NSG mice/arm, and includes a prior tolerability study (3 NSG mice/arm). The statistical association between the in vivo efficacy test outcomes and the user’s biomarkers will be tested and in case validated, providing preclinical evidence in positive cases.

To perform more complex studies, more units of access must be selected. For instance, for a 4 arms study (e.g., vehicle arm; drug A arm; drug B arm; drug A + drug B arm), two units of access are required.

The user could select the PDX model on the EurOPDX Data Portal (https://dataportal.europdx.eu/), supported by the Research Infrastructure. The costs for shipment or, in case, for buying commercial drug(s) or compound(s) to be used in the study are not included in the service.

This service is open to both Academic and Industry researchers.
EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO)University of Torino1 PDX modelhttps://www.oncology.unito.it/
3.45b_CELLAX_Exp.TherapeuticsES In vivo preclinical validation of response predictors (biomarkers).Performance of an in vivo drug efficacy study on a selected patient-derived xenografts (PDX) model. The standard service (1x Unit of Access) involves testing a user-provided drug or compound and a list of biomarkers in a 2-arms study, one control arm and one treatment arm, with 6 NSG mice/arm, and includes a prior tolerability study (3 NSG mice/arm). The statistical association between the in vivo efficacy test outcomes and the user’s biomarkers will be tested and in case validated, providing preclinical evidence in positive cases.

To perform more complex studies, more units of access must be selected. For instance, for a 4 arms study (e.g., vehicle arm; drug A arm; drug B arm; drug A + drug B arm), two units of access are required.

The user could select the PDX model on the EurOPDX Data Portal (https://dataportal.europdx.eu/), supported by the Research Infrastructure. The costs for shipment or, in case, for buying commercial drug(s) or compound(s) to be used in the study are not included in the service.

This service is open to both Academic and Industry researchers.
EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO)Vall d'Hebron Institute of Oncology1 PDX modelhttps://vhio.net/
3.10_SINTEFNOMiSeq sequencing, applicable to biological samples from patients, microbiota, and cells. MiSeq sequencing, applicable to biological samples from patients, microbiota, and cells. Bioinformatic pipelines for processing of genomic, metagenomic and transcriptomic data. ddPCR and RT-PCR for targeted nucleic acid quantification and characterizationEUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC)SINTEF ASMiSeq sequencing 3-months projecthttps://www.sintef.no/en/
3.11_SINTEFNOEstablished robotic methods for cytokine and protein quantification by antibody-based technologiesEstablished robotic methods for cytokine and protein quantification by antibody-based technologies that can be developed further for new targets. Shotgun proteomics for characterization of samples, e.g., from exosomes/EvsEUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC)SINTEF ASCytokine and protein quantif 2-months projecthttps://www.sintef.no/en/
3.12_SINTEFNOMicro- and nanofabrication for development and production of diagnostic and separation devices.Micro- and nanofabrication for development and production of diagnostic and separation devices. Including already developed microfluidic systems for exosome isolation and subsequent biomarker detectionEUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC)SINTEF ASMicro and nanofabrication 3-months projecthttps://www.sintef.no/en/
3.13_CIPFESExoscreen from biofluids (using Alphascreen Technology)Quantification of number of exosomes by alphascreen technology. Simultaneous determination of tetraspanins CD9-CD63 in donor and acceptor bead. Sample volume minimum 5 ul, any biological fluids could be studies (also patient-derived). Prior analysis by NTA could be also provided. Please see details in ref DOI: 10.7150/ntno.73606EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC)Centro de Investigación Príncipe Felipe Exoscreen (sample)http://www.VicentResearchLab.com
3.18_CIPF LaFeESNMR-Metabolomics-Jet robotic sample changer for analysis of clinical samples (biofluids, tissue), cell extracts, etc 1H-NMR characterization of the metabolic profile of biological samples (biofluid, tissue, etc). The service includes sample preparation and NMR spectra acquisition protocols for different biological matrices (serum, plasma, urine, tissue extract, cell extract, vaginal fluid, faeces, etc). Spectra will be automatically phased and baseline corrected, chemical shift referenced internally to the methyl group signal of alanine at 1.47 ppm (serum) or TSP at 0.00 ppm (urine) using TopSpin 3.1 (Bruker Biospin). Metabolites signals will be identified using AMIX v 3.9.7 (Bruker Biospin) in combination with the Bruker NMR Metabolic Profiling Database BBIOREFCODE 2.0.0 database, and other public databases.EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC)Centro de Investigación Príncipe Felipe NMR-Metabolomic analysis (sample)http://www.VicentResearchLab.com
3.7_MEDINAESMetabolomic profiling of cancer stem cell-derived exosomes Analysis of metabolite profile of cancer stem cell-derived exosomes by Liquid Chromatography and High Resolution Mass Spectrometry, and identification of major components from targeted analysis.EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC)Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía Exosome analysis (sample)https://www.medinadiscovery.com/
3.8_MEDINAESUntargeted LC-HRMS metabolomics for cancer biomarkers (breast, pancreatic ductal adenocarcinoma, lung cancer, hematological cancer)Identification of differential metabolites from biological samples by untargeted metabolomic analysis by Liquid Chromatography and High Resolution Mass Spectrometry. (Analytical validation using principal component analysis; Statistical analysis (univariate and multivariate analysis) and tentative identification of biomarkers as differential metabolitesEUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC)Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía Untargeted metabolome biomaker analysis (project)https://www.medinadiscovery.com/
3.9_USCESDevelopment of immunophenotyping assays from patient samples (USC) The immunophenotyping for biomarkers from patient material will be carried out by means of Luminex measurements of up to 30 cytokines per patient sample.EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC)University of Santiago de Compostela3-months project (immunophenotyping assay)https://www.usc.gal/en/department/pharmacology-pharmacy-and-pharmaceutical-technology
3.1_Instruct_NMRCZSolution NMR, Brno, Czech Republic - canSERVThe Core Facility of High Field NMR Spectroscopy at CEITEC Instruct centre provides access to NMR spectrometers in the range of proton frequencies from 500 MHz to 950 MHz. The equipment is suited mainly to the studies of structure, dynamics and interactions of biomolecules, i.e. proteins, nucleic acids and carbohydrates. However, the instrumentation is flexible enough to cover various research needs in material science, organic and inorganic chemistry, biochemistry, biology and biophysics.INSTRUCT-ERICInstruct Centre CZ - CEITEC1 dayhttps://www.ceitec.eu
3.2_Instruct_MSGBMass Spectrometry, Leeds, UK - canSERVServices include hydrogen/deuterium exchange (HDX)-MS analyses to determine protein folding states, effects of ligand binding and protein interactions (e.g. epitope mapping); Covalent labelling setup for hydroxyl radical foot printing via Fast Photochemical Oxidation of Proteins (FPOP) linked to mass spectrometry, to probe changes in solvent accessibility; High-resolution native MS (for heterogeneous systems at high mass-to-charge ratios, e.g. membrane protein lipid complexes); Ion mobility capabilities INSTRUCT-ERICInstruct Centre UK - Astbury Biostructure Laboratory1 dayhttps://www.astbury.leeds.ac.uk

More information about individual services, please contact us.